Stanford Med Students Offered Option to Study Their Own Genotype Data
By GenomeWeb,
GenomeWeb Daily News
| 06. 07. 2010
Stanford University School of Medicine today said that it will offer a new course that gives medical and graduate students an option to study their personal genotype data.
The university said that it believes it is the first medical school to offer students such a course. However, the University of Pennsylvania School of Medicine offered its fourth-year medical students a similar course in personalized medicine this past year.
In the Stanford course, students will learn how to analyze, evaluate, and interpret the genetic data, the limitations of existing technologies, and the legal and ethical issues surrounding personal genotyping.
The course will be an elective and will be offered during the school's summer quarter, which begins June 21.
The UPenn course also included a discussion of the ethical, legal, and social implications of personalized medicine, according to Professor Reed Pyeritz, who offered the course and is director of the school's Center for the Integration of Genetic Healthcare Technologies. Students in the UPenn course were offered an option to have their genome scanned by the Coriell Personalized Medicine Collaborative.
Recently, the University...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
